U.S. markets open in 7 hours 50 minutes
  • S&P Futures

    3,732.50
    +0.50 (+0.01%)
     
  • Dow Futures

    29,760.00
    +10.00 (+0.03%)
     
  • Nasdaq Futures

    11,538.00
    -17.75 (-0.15%)
     
  • Russell 2000 Futures

    1,722.10
    +1.30 (+0.08%)
     
  • Crude Oil

    81.78
    -0.37 (-0.45%)
     
  • Gold

    1,658.70
    -11.30 (-0.68%)
     
  • Silver

    18.73
    -0.15 (-0.82%)
     
  • EUR/USD

    0.9674
    -0.0065 (-0.67%)
     
  • 10-Yr Bond

    3.7050
    0.0000 (0.00%)
     
  • Vix

    30.18
    -2.42 (-7.42%)
     
  • GBP/USD

    1.0772
    -0.0114 (-1.04%)
     
  • USD/JPY

    144.5950
    +0.4730 (+0.33%)
     
  • BTC-USD

    19,525.10
    +769.73 (+4.10%)
     
  • CMC Crypto 200

    445.96
    +17.18 (+4.01%)
     
  • FTSE 100

    7,005.39
    +20.80 (+0.30%)
     
  • Nikkei 225

    26,442.68
    +268.70 (+1.03%)
     

Ascendis Pharma's (NASDAQ:ASND) investors will be pleased with their incredible 399% return over the last five years

·3 min read

It hasn't been the best quarter for Ascendis Pharma A/S (NASDAQ:ASND) shareholders, since the share price has fallen 24% in that time. But that doesn't change the fact that the returns over the last half decade have been spectacular. In that time, the share price has soared some 399% higher! Arguably, the recent fall is to be expected after such a strong rise. Of course what matters most is whether the business can improve itself sustainably, thus justifying a higher price.

Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.

View our latest analysis for Ascendis Pharma

Because Ascendis Pharma made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

For the last half decade, Ascendis Pharma can boast revenue growth at a rate of 16% per year. That's well above most pre-profit companies. Fortunately, the market has not missed this, and has pushed the share price up by 38% per year in that time. It's never too late to start following a top notch stock like Ascendis Pharma, since some long term winners go on winning for decades. On the face of it, this looks lke a good opportunity, although we note sentiment seems very positive already.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

Ascendis Pharma is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

While the broader market gained around 4.5% in the last year, Ascendis Pharma shareholders lost 21%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 38% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Ascendis Pharma better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 4 warning signs with Ascendis Pharma , and understanding them should be part of your investment process.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.